01 September 2025
01 September 2025
Soaring rebate rates could dissuade drug developers from launching new medicines in the UK, some critics argue.
Although Saxenda is the first generic GLP-1 to hit the US market, its sales will likely be overshadowed by next-gen drugs such as Wegovy and Zepbound.
The subcutaneous injection will remove the need for patients to visit infusion centres.
Wayrilz achieved primary and secondary goals in the LUNA 3 phase III trial, which backed the approval process.
The jab will be included as part of a revamped MMRV combined vaccine from January 2026.
Sales of the drug to the Indian market will commence in the fourth quarter of 2025.
The authorisation is based upon results from the Phase III SELECT-GCA trial.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
